

Mycenax Biotech Inc.

Board of Directors' Expertise and Diversity

1. Directors

1.1 Disclosure of information on the professional qualifications of directors and the independence of independent directors:

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
Chairman Center Laboratories, Inc. Representative: Pei-Jiun Chen	<p>After graduating from the Department of Animal Science at National Taiwan University, Director Pei-Jiun Chen went to the United States and obtained a Ph.D. in Biology from the University of Michigan. She has previously served as a postdoctoral researcher at academic institutions such as Stanford University in the United States and the University of Lausanne in Switzerland. In both domestic and global biotech companies, she was responsible for the early development of biopharmaceuticals and the expansion of CRO business, successfully expanding business to Japan, South Korea, Singapore, Europe, India, and the Middle East.</p> <p>Since 2019, she has served as the General Manager of Mycenax Biotech Inc. In addition to licensing biosimilar products to internationally renowned pharmaceutical company, she has also led</p>	<ol style="list-style-type: none"> 1. No family relationship with the current director. 2. Concurrently serve as the general manager of the Company. 	0	

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
		<p>the team to transform into a CDMO company, achieving a 29.36% CAGR and more than three times the increase in production capacity. Since 2022, she has also served as the Chairman of the Board. Director Pei-Jiun Chen has extensive experience and expertise in biopharmaceutical development, strategic planning and management, business transformation, and market development.</p>		
<p>Director Center Laboratories, Inc. Representative: Chun-Hong Chen</p>		<p>Director Chun-Hong Chen graduated from the Department of Business Administration at Union University of United States. The experience of Director Chun-Hong Chen covers securities, banking, biotechnology and conventional industries. He worked in Chia Her Industrial Co., Ltd., entered the securities industry as a deputy general manager in 1997 and was in charge of investment business. In 2003, he became the general manager of MicroBio Co., Ltd. Mr. Chen has been serving as the Chairman of Yuanfu Securities since 2007. He has successfully guided many well-known biotechnology companies to go public and is an important promoter for the domestic biotechnology industry to enter the capital market. Mr. Chen also concurrently serves as the Chairman of MasterLink Venture Capital Corporation, director of Shin Kong Commercial Bank Co., Ltd., and director of Taipei Exchange. Mr. Chen has profound experience and expertise in capital planning, securities investment, industry research, business operation and corporate governance.</p>	<p>There is no family relationship with the current directors and members of the management team.</p>	<p>0</p>

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
Director JCR Pharmaceuticals Co., Ltd. Representative: Yoh Ito	Director Yoh Ito graduated from the Department of Economics at the University of Tokyo and holds an MBA from Cornell University in the United States. He has worked in international finance at the Industrial Bank of Japan, where he advised companies on the verge of bankruptcy, and has also worked as a financial and strategic planning consultant at consulting firms. Since 2003, he has served as the finance director at KYORIN Pharmaceutical in Japan, where he has been responsible for planning and executing financial strategies. He is currently a senior executive director at JCR Pharmaceutical in Japan. Director Yoh Ito has extensive experience and expertise in financial strategic planning, execution, and advising in the biotechnology industry, as well as in accounting practices, enterprise management, and corporate governance.	There is no family relationship with the current directors and members of the management team.	0	
Director Nien Hsing International Investment Co., Ltd. Representative: En-Tzn Liu	Director En-Tzn Liu graduated from the Master of Accounting at National Taiwan University and previously worked as a deputy manager at KPMG. Currently, she serves as the finance and accounting officer as well as the corporate governance officer at Nien Hsing International Investment Co., Ltd. Director En-Tzn Liu has extensive practical experience in accounting and financial planning.	There is no family relationship with the current directors and members of the management team.	0	
Director Jason Technology Co., Ltd. Representative: Chia-Ling Lin	Director Chia-Ling Lin graduated from the Economics Department at McMaster University in Canada. With more than 10 years of experience in management roles in several biotech companies,	There is no family relationship with the current directors and members of	0	

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
		<p>Director Chia-Ling Lin is currently the post-investment management manager at BioEngine Technology Development Inc., a subsidiary of Center Laboratories Group. During her time at BioEngine Technology Development Inc., she has been involved in venture capital operations and successfully planned and implemented transformation plans for multiple companies, utilizing her expertise in investment research, analysis, and post-investment management to help these companies achieve specific success goals.</p>	<p>the management team.</p>	
<p>Director China Investment and Development Co., Ltd. Representative: Hsiu-Yuan Lee</p>	<p>Director Hsiu-Yuan Lee graduated from the Economics Department at San Jose State University in the United States with a master's degree. Her previous experience includes working in the securities and investment industries, where she has assessed more than 200 investment cases in the semiconductor, optoelectronics, and information electronics industries. She has invested in more than 20 companies, with over 10 companies going public. Currently, she serves as the General Manager of China Investment and Development Co., Ltd. and sits on the board of directors for several biotechnology companies.</p> <p>Director Hsiu-Yuan Lee has many years of experience in securities and venture capital investment, which has allowed her to establish a wide range of investment projects and networks among technology industry insiders, research institutions, venture capital, underwriters, and investment advisers.</p>	<p>There is no family relationship with the current directors and members of the management team.</p>	<p>0</p>	

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
Independent Director Kuo-Pin Kao	Independent Director Kuo-Pin Kao assumes the role of convener of the Audit Committee for the company and possesses specialized knowledge in accounting and finance. Independent Director Kuo-Pin Kao graduated from the Department of Economics at National Chung Hsing University. He has previously served as the Chairman of MasterLink Futures, General Manager of MasterLink Securities, and Chairman of Global Securities. In addition, he has served as an independent director for Mycenax Biotech for many years. Director Kuo-Pin Kao is well-versed in securities investment, financial strategy planning, and corporate management, with extensive experience and expertise in these areas. He also has a deep understanding of the management and operations of the biotechnology industry.	1. Including but not limited to whether the members, their spouses, or relatives within the second degree of kinship are the directors, supervisors or employees of the Company or its affiliated companies: None.	0	
Independent Director Yu-Sheng Tsai	Independent Director Yu-Sheng Tsai graduated from the Department of Law at National Chung Hsing University (now National Taipei University), Master of Law at Fu Jen Catholic University, and the EMBA Program at National Chengchi University. He is a practicing lawyer who passed the bar exam. Director Yu-Sheng Tsai has previously served as legal counsel for various industries, including finance, telecommunications, and manufacturing. He has also served as a legal consultant for many years for the Bureau of Energy, Ministry of Economic Affairs and the Institute for Information Industry. Currently, he is the founder and director of a professional consulting firm at Genda Law Firm, an arbitrator for the	2. the number and percentage of the shares of the Company held by the members, their spouses, relatives within the second degree of kinship (or held in the	1	

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
	Chinese Arbitration Association, Taipei, and an honored lawyer for Small and Medium Enterprises Administration, Ministry of Economic Affairs. Director Yu-Sheng Tsai has extensive knowledge and expertise in law, as well as a thorough familiarity with the operations and management of various industries.	name of another person): None.	3. whether they are the directors, supervisors or employees of a company which has a specific relationship with the Company (please refer to the provisions in the subparagraphs 5 to 8 of paragraph 1 of Article 3 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies): None	
Independent Director Allen Y Chao	Independent Director Allen Y Chao graduated from the Department of Pharmacy at Taipei Medical University and then earned his Ph.D. in Pharmaceutical Engineering from Purdue University in the United States. After working in the US for several years, he founded Watson Pharmaceuticals, which eventually became the third-largest generic drug company in the US, with a market value exceeding \$100 billion. After retiring from Watson in 2008, he founded Tanvax BioPharma Inc. in both Taiwan and the US in response to the US healthcare reform that opened up the production of biosimilar drugs. Currently, he serves as the chairman of Newport Healthcare Advisors, as well as a board member for several other biotech companies. Director Allen Y Chao with over 40 years of experience in R&D, market development, strategic planning, management, and investment in the biotech industry both domestically and internationally.			0

Name	Qualification	Professional qualification and experience(Note 1)	Independence Analysis	Number of public companies that the Independent Director also holds the position as independent director
			<p>4. the amount of remuneration received for providing business, legal, financial, accounting and other services to the Company or its affiliates in the last two years: None</p>	

Note 1. None of the directors falls under the circumstances stipulated in Article 30 of the Company Law.

1.2 Diversity and independence of the Board of Directors:

The Company advocates and respects a policy of board diversity, in order to strengthen corporate governance and promote the sound development of the board composition and structure. We believe that a diverse policy will help to enhance overall company performance. The selection of board members is based on the principle of recruiting talent and competency, possessing diverse complementary capabilities across industries, including basic components such as age, gender, nationality, etc., as well as industry experience and related skills in biotech, finance, securities, investment, law, etc., and abilities in business judgment, management, leadership, decision-making, and crisis management. In order to strengthen the board function to achieve ideal corporate governance, Article 20 of the Company's "Corporate Governance Best Practice Principles ", specifies the following capabilities that the board as a whole should possess:

Name	Diversified items	Gender	Nationality	Age	Term of service for Independent Directors	Business Judgment	Accounting and Financial analysis	Operational management	Crisis Management	Industry knowledge	International Market View	Leadership and Decision-Making
Center Laboratories, Inc. Representative: Pei-Jiun Chen		Female	ROC	51-60	—	✓	—	✓	✓	✓	✓	✓
Center Laboratories, Inc. Representative: Chun-Hong Chen		Male	ROC	61-70	—	✓	✓	✓	✓	✓	✓	✓
JCR Pharmaceuticals Co., Ltd. Representative: Yoh Ito		Male	Japan	61-70	—	✓	✓	✓	✓	✓	✓	✓
Nien Hsing International Investment Co., Ltd. Representative: En-Tzn Liu		Female	ROC	31-40	—	✓	✓	✓	✓	✓	✓	✓
Jason Technology Co., Ltd. Representative: Chia-Ling Lin		Female	ROC	31-40	—	✓	✓	✓	✓	✓	✓	✓
China Investment and Development Co., Ltd. Representative: Hsiu-Yuan Lee		Female	ROC	51-60	—	✓	✓	✓	✓	✓	✓	✓
Kuo-Pin Kao		Male	ROC	61-70	More than three*	✓	✓	✓	✓	✓	✓	✓

Name	Diversified items	Gender	Nationality	Age	Term of service for Independent Directors	Business Judgment	Accounting and Financial analysis	Operational management	Crisis Management	Industry knowledge	International Market View	Leadership and Decision-Making
Yu-Sheng Tsai		Male	ROC	41-50	Less than three	✓	—	✓	✓	✓	✓	✓
Allen Y Chao		Male	USA	71-80	Less than three	✓	—	✓	✓	✓	✓	✓

* Although Mr. Kuo-Pin Kao, an independent director, has served for three consecutive terms, the Company still values his professional insights and guidance on future development. The Board of Directors believes that Mr. Kao continues to maintain the necessary independence and has not established any relationship with the management (or others) that may undermine his impartial judgment based on the best interests of the Company or his ability to perform duties without bias.

1.1.1 The 10th Board of Directors of the Company consists of 9 members, including 3 independent directors, who possess a range of capabilities including Business Judgment, Operational management, Crisis Management, Industry knowledge, International Market View, Leadership and Decision-making, as well as Industry experience and professional skills. Chairman Pei-Jiun Chen and Independent Director Allen Y Chao are experienced in the biotechnology industry; Director Chun-Hong Chen, Hsiu-Yuan Lee, Chia-Ling Lin, and Independent Director Kuo-Pin Kao are proficient in securities investment; Independent Director Yu-Sheng Tsai has extensive experience in legal affairs; while Director Yoh Ito, En-Tzn Liu and Independent Director Kuo-Pin Kao possess financial expertise and experience.

1.1.2 Two directors are foreigners, one is Japanese, one is American, and the remaining seven directors are Taiwanese. Three independent directors accounting for 33% of the total board of directors. Except for Chairman and General Manager Pei-Jun Chen, all other directors do not hold employee positions. In terms of age distribution, three directors are under 50 years old, two directors are between 51 and 60 years old, and four directors are over 61 years old. In addition to independent director Kuo-Pin Kao 's consecutive term, other directors are limited to serving no more than three terms. The Company also values gender equality in the composition of the board. The current board includes four female members, accounting for 44% of the total directors, and

we will continue to strive to maintain or increase the ratio of female directors in the future.

- 1.1.3 The diversity, complementarity, and implementation status of the board of directors are already included in the standards in Article 20 of the Company's "Corporate Governance Best Practice Principles". In the future, we will continue to amend our diversity policies in a timely manner based on the operation of board, the business model, and development needs. These amendments include but are not limited to standards related to the two major dimensions of basic conditions and values, professional knowledge and skills, and other relevant areas. We aim to ensure that board members possess the necessary knowledge, skills, and qualities to perform their duties effectively.
- 1.1.4 There is no spouse or first-degree relative relationship between the directors of the Company, which is in compliance with the provisions of Articles 26-3(3) and 26-3(4) of the Securities and Exchange Act.